BackARCA biopharma Overview

ARCA biopharma Receivables

Track ARCA biopharma's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

ARCA biopharma Receivables History

Loading

ARCA biopharma vs. peers: Receivables Comparison

Loading

ARCA biopharma Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

ARCA biopharma (ABIO) FAQ

ARCA biopharma (ABIO) currently reports a receivables of $0 as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore ARCA biopharma's receivables history and peer comparisons.

ARCA biopharma's receivables changed from $0 to $0 (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ARCA biopharma reported $0 in receivables as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ARCA biopharma, and consider following ABIO for alerts when major investors trade the stock.

ARCA biopharma is classified in the Healthcare sector. On receivables, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ABIO with unrelated industries.